Literature DB >> 12371135

Immunohistochemical evidence of lactoferrin in hepatic biopsies of patients with viral or cryptogenetic chronic liver disease.

G Tuccari1, D Villari, G Giuffrè, A Simone, G Squadrito, G Raimondo, G Barresi.   

Abstract

Lactoferrin (Lf) expression has been immunohistochemically investigated in 117 formalin-fixed paraffin-embedded liver bioptic samples obtained from an equal number of patients affected by chronic hepatitis (HCV = 76; HBV = 17; HBV + HDV = 14; cryptogenetic = 10); in addition, 10 autoptic specimens of normal liver were studied as control. The Lf immunoreactivity was evaluated by an intensity-distribution (ID) score. The Lf immunoexpression was observed in 88 out of 117 (75%) cases of chronic hepatitis; interestingly, all liver specimens from HBV hepatitis showed a constant Lf reactivity with the highest ID-score, whereas the evidence of Lf was encountered in 54/76 (71.1%) HCV as well as in 11/14 (78.6%) HDV chronic hepatitis, thus documenting a variable degree of Lf immunostaining in relation to different viruses. Moreover, in 6/10 (60%) cases of cryptogenetic hepatitis Lf immunoexpression was documented, whereas all normal liver controls were unreactive. In HCV specimens, the Lf nuclear immunoreactivity appeared to increase with the progression of the disease, with a greater expression in genotype 1. In contrast, no relationship among Lf ID-scores and different stages or grades of HBV, HDV or cryptogenetic hepatitis was encountered. This fact may suggest a role for Lf as an unspecific defensive agent in chronic inflammatory liver diseases, similarly to that elsewhere reported in other inflammatory tissue injuries.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12371135     DOI: 10.14670/HH-17.1077

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  3 in total

1.  Lactoferrin immuno-expression in human normal and neoplastic bone tissue.

Authors:  Antonio Ieni; Valeria Barresi; Maddalena Grosso; Michele Attilio Rosa; Giovanni Tuccari
Journal:  J Bone Miner Metab       Date:  2009-02-26       Impact factor: 2.626

2.  Usefulness of ascitic fluid lactoferrin levels in patients with liver cirrhosis.

Authors:  Sang Soo Lee; Hyun Ju Min; Ja Yun Choi; Hyun Chin Cho; Jin Joo Kim; Jae Min Lee; Hong Jun Kim; Chang Yoon Ha; Hyun Jin Kim; Tae Hyo Kim; Jin Hyun Kim; Ok-Jae Lee
Journal:  BMC Gastroenterol       Date:  2016-10-13       Impact factor: 3.067

3.  Immunoexpression of lactoferrin in bone metastases and corresponding primary carcinomas.

Authors:  A Ieni; V Barresi; G Branca; G Giuffrè; M A Rosa; G Tuccari
Journal:  Oncol Lett       Date:  2013-03-05       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.